A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly

Clinical Endocrinology

Volumn 71, Issue 4, 2009, Pages 549-557

  Trainer, Peter J ^a   Ezzat, Shereen ^b   D'Souza, Gwyn A ^c   Layton, Gary ^c   Strasburger, Christian J ^d  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b MOUNT SINAI HOSPITAL   (Canada)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C;

ACROMEGALY; ADIPOSE TISSUE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GROWTH HORMONE BLOOD LEVEL; HUMAN; INJECTION SITE REACTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PITUITARY TUMOR VOLUME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TUMOR VOLUME; URIC ACID BLOOD LEVEL;

ACROMEGALY; ADULT; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIVER; MALE; MIDDLE AGED; OCTREOTIDE;

EID: 69949142355     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2009.03620.x     Document Type: Article

References (24)

1. AACE Acromegaly Guidelines Task Force (2004) AACE medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocrine Practice, 10, 213 225.
2. Swearingen, B., Barker, F.G. 2nd., Katznelson, L. et al. (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism, 83, 3419 3426.
3. Holdaway, I.M., Rajasoorya, R.C. Gamble, G.D. (2004) Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism, 89, 667 674.
4. Colao, A., Pivonello, R., Auriemma, R.S. et al. (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. European Journal of Endocrinology, 154, 467 477.
5. Freda, P.U. (2002) Somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism, 87, 3013 3018.
6. Kopchick, J.J., Parkinson, C., Stevens, E.C. et al. (2002) Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocrine Reviews, 23, 623 646.
7. Trainer, P.J., Drake, W.M., Katznelson, L. et al. (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine, 342, 1171 1177.
8. van der Lely, A.J., Hutson, R.K., Trainer, P.J. et al. (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet, 358, 1754 1759.
9. Barkan, A.L., Burman, P., Clemmons, D.R. et al. (2005) Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. Journal of Clinical Endocrinology and Metabolism, 90, 5684 5691.
10. van der Lely, A.J., Muller, A., Janssen, J.A. et al. (2001) Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. Journal of Clinical Endocrinology and Metabolism, 86, 478 481.
11. Jorgensen, J.O., Feldt-Rasmussen, U., Frystyk, J. et al. (2005) Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. Journal of Clinical Endocrinology and Metabolism, 90, 5627 5631.
12. Feenstra, J., de Herder, W.W., ten Have, S.M. et al. (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet, 365, 1644 1646.
13. Neggers, S.J., van Aken, M.O., Janssen, J.A. et al. (2007) Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. Journal of Clinical Endocrinology and Metabolism, 92, 4598 4601.
14. Lundin, P. Pedersen, F. (1992) Volume of pituitary macroadenomas: assessment by MRI. Journal of Computer Assisted Tomography, 16, 519 528.
15. Webb, S.M., Prieto, L., Badia, X. et al. (2002) Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clinical Endocrinology, 57, 251 258.
16. Kind, P., Dolan, P., Gudex, C. et al. (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. British Medical Journal (Clinical research ed.), 316, 736 741.
17. Elmlinger, M.W., Kuhnel, W., Weber, M.M. et al. (2004) Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clinical Chemistry and Laboratory Medicine, 42, 654 664.
18. Feenstra, J., van Aken, M.O., de Herder, W.W. et al. (2006) Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. European Journal of Endocrinology, 154, 805 806.
19. Clemmons, D.R. (2004) The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. Journal of Clinical Investigation, 113, 25 27.
20. Kasayama, S., Otsuki, M., Takagi, M. et al. (2000) Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clinical Endocrinology, 52, 549 555.
21. Koop, B.L., Harris, A.G. Ezzat, S. (1994) Effect of octreotide on glucose tolerance in acromegaly. European Journal of Endocrinology, 130, 581 586.
22. Drake, W.M., Rowles, S.V., Roberts, M.E. et al. (2003) Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. European Journal of Endocrinology, 149, 521 527.
23. Rose, D.R. Clemmons, D.R. (2002) Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Hormone and IGF Research, 12, 418 424.
24. Parkinson, C., Drake, W.M., Roberts, M.E. et al. (2002) A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. Journal of Clinical Endocrinology and Metabolism, 87, 1797 1804.